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Intratumoural hypoxia (low oxygen tension) is associated with aggressive disease and poor prognosis. Hypoxia-inducible factor-1
is a transcriptionfactor activated by hypoxia thatregulates the expression of genes that promote tumour cell survival, progression,
metastasis, and resistance to chemo/radiotherapy. In addition to hypoxia, HIF-1 can be activated by growth factor-signalling
pathways such as the mitogen-activated protein kinases- (MAPK-) and phosphatidylinositol-3-OH kinases- (PI3K-) signalling
cascades. Mutations in these pathways are common in thyroid carcinoma and lead to enhanced HIF-1 expression and activity.
Here, we summarise current data that highlights the potential role of both hypoxia and MAPK/PI3K-induced HIF-1 signalling
in thyroid carcinoma progression, metastatic characteristics, and the potential role of HIF-1 in thyroid carcinoma response to
radiotherapy. Direct or indirect targeting of HIF-1 using an MAPK or PI3K inhibitor in combination with radiotherapy may be a
new potential therapeutic target to improve the therapeutic response of thyroid carcinoma to radiotherapy and reduce metastatic
burden.
1.Introduction
The hypoxia-inducible factors (HIFs) are transcription fac-
tors that function under low oxygen tensions (hypoxia) and
are, therefore, active in a number of diseases associated with
low oxygen (O2) environments. These include ischemic dis-
orders, atherosclerosis, and importantly cancer. HIF drives
the survival and development of cancer cells by activating
andrepressing amultitudeofgenesthatpromotetumourcell
survival, proliferation, invasion, and disease progression. As
a result, hypoxia and HIF are associated with poor prognosis
in many tumour types [1–3]. Hypoxia occurs in the majority
of solid tumours, thus functional HIF is present in most
tumour types indicating the importance of this signalling
pathway in cancer. There is little known, however, about
the role of HIF in thyroid carcinoma. Here, we summarise
current literature that supports the potential signiﬁcance of
theHIF signalling pathway in progression and aggressiveness
of thyroid carcinoma. Current data proposes that the HIF
pathway may be a novel therapeutic target in reducing
local tumour growth, metastatic burden, and resistance to
chemo/radiotherapy.
2.Oxygen-DependentRegulationof HIF-1
There are three known isoforms of HIF: HIF-1, 2, and 3.
HIF-1 is expressed in all cells and is the most extensively
researched, whereas the expression of the other isoforms
is restricted to certain tissues. HIF-1 is a heterodimeric
protein consisting of a constitutively expressed HIF-1β
(also known as the ary lhydrocarbon receptor nuclear
translocator; ARNT) subunit and an oxygen-labile HIF-
1α subunit. Under conditions of low oxygen, HIF-1α is
stabilised, heterodimerises with HIF-1β through the Per-
ARNT-Sim (PAS) A and PAS B domains, and translocates
to the nucleus. The complex then binds to the hypoxia-
responsive element (HRE; consensus sequence G/ACGTG),
in the promoter region of target genes via the basic helix-
loop-helix(bHLH)DNA-bindingdomainandactivatestran-
scription. This process involves binding of the coactivators
CREB-binding protein (CBP) and p300 [4, 5].2 Journal of Thyroid Research
Under normoxia, HIF-1α is hydroxylated on proline
residues 402 and/or 564 in the oxygen-dependent degrada-
tion domain (ODD). This process is carried out by speciﬁc
oxygen-dependent enzymes known as proline hydroxylase
d o m a i np r o t e i n s( P H D s ) .T h e r ea r e3P H D s :1 ,2 ,a n d3 .
PHD2isspeciﬁcally involvedinthehydroxylation ofHIF-1α.
The PHDs use O2 and 2-oxoglutarate (2-OG) as substrates.
Upon hydroxylation, von Hippel-Lindau (VHL), a tumour-
suppressor protein, binds HIF-1α and recruits the E3
ubiquitin ligase, leading to ubiquitination and proteosomal
degradation of HIF-1α (Figure 1). Activation of asparaginyl
hydroxylases such as factor inhibiting HIF-1 (FIH-1) repre-
sents an additional oxygen-dependent mechanism of inhi-
bition of HIF-1α activity. FIH-1 hydroxylates asparagine-
803 in the C-terminal transcriptional activation domain (C-
TAD) of HIF-1α. This modiﬁcation inhibits the interaction
of C-TAD with the transcriptional co-activators CBP/p300,
and thus inhibits the transcriptional activity of HIF-1
(Figure 1). Underhypoxia, the level of HIF-1α hydroxylation
is reduced via inhibition of the PHD2 enzyme, resulting in
stabilisation and accumulation of HIF-1α protein [4, 5]. An
additional oxygen-sensitive mechanism of HIF-1 regulation
is the generation of reactive oxygen species (ROS) from
mitochondria. ROS inactivate PHD2 resulting in direct
stabilisation of HIF-1α [6].
HIF-2α is likewise regulated by oxygen-dependent hy-
droxylation and dimerises with HIF-1β to form the func-
tional HIF-2 complex [4, 7]. Both isoforms are similar in
structure and function but have diﬀerences, particularly in
the N-TADs [8]. This suggests that both isoforms may diﬀer
in the activation of target genes and the recruitment of
coactivators. There are also fewer HIF-2α-regulated genes
compared to HIF-1α. For example, in MCF-7 breast carci-
noma cells, 80% of hypoxia-regulated genes were dependent
on HIF-1α. A small group were dependent on HIF-2α,a n d
the regulation of these genes was due to the interaction
of HIF-2α with the transcription factor Elk-1 [9]. This
interaction with Elk-1 is unique to HIF-2α.
Although HIF-1α and -2α show some overlap of target
genes,theproteinsdohavedistinctdownstreamtargets.HIF-
1 predominantly regulates the expression of genes encoding
glycolytic proteins such as lactate dehydrogenase-A (LDH-
A) and carbonic anhydrase-9 (CA-9), whereas in certain
tissues expressing both HIF-1 and -2α, expression of genes
such as vascular endothelial growth factor (VEGF) and
erythropoietin (EPO) is mainly regulated by HIF-2α [7,
10, 11]. In support of this, high expression of HIF-2α
but not -1α has been found in well-vascularised areas of
neuroblastoma and is associated with aggressiveness [12].
Although HIF-1α is accepted as the most important of the
HIFs, there is increasing evidence suggesting that HIF-2α
may be of equal signiﬁcance. The expression of HIF-2α
is both tissue and cell-type speciﬁc, and the regulation of
target genes diﬀers depending on tissue type, tumour type,
and coexpression with HIF-1α. A better understanding of
how these factors lead to cell-speciﬁc diﬀerences in HIF-
dependent gene regulation may help in the development of
more eﬀective therapeutics for diseases highly dependent on
hypoxia. The HIF-3α isoform is also hypoxia regulated in
a HIF-1-dependent manner and is an inhibitor of HIF-1
function [13].
3.OxygenIndependentMechanisms of
HIF Activation
3.1. Mutations in VHL. VHL targets all the HIF-αsf o rr a p i d
proteosomal degradation and, as a result, plays a central role
inmolecularoxygensensing [14].Studiesintothephenotype
of VHL knockout (KO) mice provide direct evidence for
the physiological relevance of the HIF pathway and VHL-
regulated expression of HIF-1α in both normal foetal devel-
opment and cancer progression. Genetic knock-out of VHL
inthemurinegermlineresultsinembryoniclethalityinmid-
gestation due to abnormal vasculature formation thought
to be HIF dependent [15]. In certain hereditary cancers
such as clear cell renal carcinomas, Chuvash polycythemia,
pheochromocytomaofthecentralnervoussystemorheman-
gioblastoma of the retina, normoxic degradation of HIF
are impaired due to mutations in VHL. These tumours are
usually well vascularised, a characteristic largelyattributedto
deregulated HIF-1α signalling [16, 17].
3.2. Metabolic Signalling Pathways. Metabolic signalling
pathways such as the tricarboxylic acid (TCA) cycle are also
necessary for normal regulation of HIF-1α. In addition to
O2, PHDs require the substrates 2-OG and ascorbic acid
as a cofactor, to catalyze hydroxylation of HIF-1α.T h i s
reaction produces succinate and CO2 as byproducts. 2-OG
is a metabolite of the TCA cycle. As 2-OG is required for
the functionality of PHDs, activity of the TCA cycle regu-
lates PHD activity and thus HIF-1α stability. Furthermore,
inactivating mutations in enzymes of the TCA cycle leads
to direct stabilisation of HIF-1α protein [18, 19]. Mutations
in fumarate hydratase (FH) and succinate dehydrogenase
(SDH)lead to accumulation of fumarate and succinate. Both
fumarate and succinate inhibit PHDs by competing with
2 - O Gf o rb i n d i n gt ot h ea c t i v es i t e[ 20, 21]. Inactivating
mutations in SDH have been found in a range of cancers
associated with enhanced HIF-1 and VEGF signalling.
These include renal cell carcinomas, gastrointestinal stromal
(GIST) tumours, and Carney’s syndrome [22, 23].
3.3. Growth Factor Signalling Pathways. For thyroid can-
cer the most important mutational changes occur in
the MAPK/Ras—extracellular signal-regulated kinase (ERK)
and the PI3K/AKT signalling cascades [24]. These pathways
are dominant regulators of many cellular processes including
growth, metabolism, cell survival, and angiogenesis and
are important in the coordinated interaction of cells with
the microenvironment [25, 26]. Both the MAPK and PI3K
signalling pathways increase HIF-1signalling in many cancer
types including thyroid [27–30].
3.4. HIF-1 and the MAPK Pathway. An u m b e ro fM A P K
(p38 and p38γ) and ERK1/2 (p42 and p44) isoforms have
been found to regulate HIF-1α activity in a cell-speciﬁc
manner. MAPK signalling enhances the transactivation ofJournal of Thyroid Research 3
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Figure 1: Structure of HIF-1α and the oxygen-dependent regulation of HIF-1α protein stabilisationand activation: The N-terminal regions
contain the basic helix-loop-helix (bHLH) domain involved in DNA-binding and the Per-Arnt-Sim (PAS) A and B domains required for
heterodimerisationwithHIF-1β. The oxygen-dependent degradation domain(ODD)iswhere PHD2hydroxylates proline residues P402and
P562,which enables binding ofVHL and proteosomaldegradation. The terminal transcriptional activation domains(TADs) are responsible
fortransactivationoftarget genes. TheN-TAD islocated towardstheN-terminus, withtheC-TAD located attheextreme C-terminus. Factor
inhibiting HIF-1 (FIH-1) hydroxylates asparagine H803 in the C-TAD, preventing the binding of coactivators CBP/p300, thus inhibiting
activation of HIF-1α. Both hydroxylation processes use 2-oxoglutarate (2-OG) and O2 as substrates and produce succinate and carbon
dioxide (CO2)a sb y p r o d u c t s .
HIF-1α by phosphorylation of HIF-1α co-activators and by
direct phosphorylation of HIF-1α itself. MAPK stimulation
leads to the phosphorylation of p300. This phosphorylation
facilitates binding of p300/CBP to the C-TAD and promotes
the transactivation activity of both p300/CBP and HIF-1α.
Studies suggest that MAPK does not phosphorylate FIH,
and therefore, this signalling cascade is not involved in the
oxygen-dependent regulation of HIF-1α [31]. Thus, even
thoughMAPK signalling doesnot dependonsensing oxygen
tension, activation of this signalling cascade augments the
HIF response.
Studies have shown that MAPK can directly phos-
phorylate the TADs of HIF-1α.S a n ge ta l .f o u n dt h a t
MAPK signalling leads to indirect phosphorylation of C-
TAD constructs by MAPK and direct phosphorylation of N-
TADconstructs,when expressed inEscherichia coli.H o w ev er ,
this direct phosphorylation of the TADs was not necessary
for binding of p300 and activation of HIF-1 [31]. Other
studies suggest that direct phosphorylation of HIF-1α by
MAPKs has functional consequences on HIF-1 activity. In
HeLa and CCL39 cells, p42/44 MAPK (but not p38 MAPK
and JNK) increased the transcriptional activity of HIF-1
by phosphorylation of HIF-1α and not by increasing the
level of HIF-1α protein. This was blocked by the MEK
inhibitorPD098059[32].Conversely,inHep3Band HEK293
cells, activation of the small GTPase Rac1 by hypoxia leads
to Rac1-dependent p38 MAPK signalling resulting in both
enhanced phosphorylation of the N-TAD and transcrip-
tional activity of HIF-1α [33, 34]. Another study, however,
has shown that Rac1 reduces HIF-1 activity by activating
NAPDH oxidases resulting in enhanced generation of ROS
leading to reduced HIF-1 in both normoxia and hypoxia
[35]. The eﬀect of Rac1 on MAPK signalling was not
shown in this study. Furthermore, the latter group used
8% O2 for hypoxia, whereas the ﬁrst study used 5 and 1%
O2 for hypoxia. These functional diﬀerences observed by
Rac1 may, therefore, be dependent upon O2 concentration.
Furthermore, diﬀerent cell lines were used in these studies
suggesting that these diﬀerences in Rac1 signalling may be
dependent on the activating mutation status of the MAPK
pathway in diﬀerent cell lines. Studies in HeLa cells have
also shown that direct phosphorylation of HIF-1α by p42/44
MAPKs not only leads to enhanced HIF-1 transcriptional
activity, but also promotes nuclear accumulation of HIF-1α
[36]. Thus, depending on the cell type, the MAPK signalling
cascade can enhance HIF-1 activity via activation of selective
kinases which either directly phosphorylate HIF-1α or co-
activators of HIF-1α (Figure 2).
In addition to MAPK signalling leading to enhanced
activity of HIF-1, studies have also shown that the MAPK
pathway may increase HIF-1α protein synthesis in certain
cancer types. Fukuda et al. showed that MAPK signalling
can increase HIF-1α protein synthesis in HCT116 colon
carcinoma cells. Inhibitors of MAPK blocked HIF-1α pro-
tein synthesis, and the overexpression of a constitutively
active MAPK kinase (MEK2) induced HIF-1α protein [37]
(Figure 2).
Genetic mutations in the v-raf murine sarcoma viral
oncogenehomolog B1 (BRAF)gene, which encodesa serine-
threonine kinase, result in hyperactive MAPK signalling.4 Journal of Thyroid Research
BRAFV600E is the most common genetic mutation within
papillary thyroid carcinomas (PTCs). On average, approx-
imately 50% of all PTCs harbour the BRAFV600E mutation
[38]. This BRAF mutant is constitutively active and phos-
phorylates MEK1/2 leading to hyperactive MAPK signalling
(Figure 2). It is thought that BRAF and, thus, MAPK
signalling are important in theearly stagesofthyroidtumour
developmentand predispose cellstobecomedediﬀerentiated
tumours [39–41]. This has recently been substantiated in a
mouse model of a thyroid-speciﬁc knock-in of oncogenic
BRAF (LSL-BRAFV600E/TPO-Cre), which leads to a high
f r e q u e n c yo fi n v a s i v eP T C s .T h e s em i c eh a dh i g hl e v e l so f
thyroid stimulating hormone that acted cooperatively with
oncogenic BRAF to drive tumour initiation [42].
The GTPase V-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog (KRAS) is one of three members of the RAS
family of GTPases. KRASinteracts with and activates a num-
ber of eﬀector proteins including BRAF and PI3K. Genetic
mutations in RAS leading to constitutive activity results in
hyperactivation of the PI3K/MAPK pathways, promoting
tumour progression in many cancer types including thyroid
[43] .R e c e n t l y ,i th a sb e e ns h o w nt h a tm u t a t i o n si nK R A S
or BRAF diﬀerentially regulate HIF-1α and HIF-2α in colon
carcinoma cells. Mutant KRAS enhanced expression of HIF-
1α only, whereas mutant BRAF enhanced expression of both
HIF-1α and -2α. KRAS-induced HIF-1α was dependent on
PI3K activation, whereas only HIF-2α was inhibited by the
MEK inhibitor PD089059 in BRAF mutant cells [44]. These
data highlight the complexity ofHIF induction by oncogenic
signalling cascades and may contribute to the phenotypic
diﬀerences observed not only in colon cancer but other
cancers harbouring these mutations such as thyroid.
The interplay and activation of MAPK by additional
signalling pathways promotes HIF-1 activity. In colon cancer
cells,lossofthetumoursuppressorSMAD4(mothersagainst
decapentaplegic (MAD) and the Caenorhabditis elegans
protein SMA-4) led to enhanced HIF-1α activity through the
activation of MEK-ERK and p38 MAPK by Transforming
growth factor-β (TGF-β)[ 45].
Stimulation of the MAPK cascade enhances HIF-1
signalling mainly by increasing the transcriptional activity
of HIF-1α. This will lead to increased expression of HIF-1
downstream targets under normoxic conditions and in the
presence of hypoxia will lead to a cooperative enhancement
of expression of HIF-1 target genes.
3.5. HIF-1 and the PI3K Pathway. Aberrant activation of
the PI3K pathway occurs by (a) hyperactive stimulation of
receptor tyrosine kinases (RTKs) including the insulin-like
growth factor-1 receptor (IGF-IR), the human epidermal
growth factor receptor 2 (HER2neuR), and the epidermal
growth factor receptor (EGFR) and (b) by mutational events
that occur in negative regulators of PI3K signalling such as
those in Phosphatase and tensin homolog (PTEN) and p53.
Activationof the PI3K pathway is pivotal in the development
andprogression ofthyroid canceraggressiveness and appears
to be predominantly involved in the metastatic behaviour
of these tumours [41]. Hyperactive PI3K signalling leads
to stabilisation of HIF-1α in normoxia. This depends on
the activation of AKT and subsequently mammalian target
of rapamycin (mTOR), which increases the translation and
activity of HIF-1α [37, 41, 46, 47].
mTOR is a serine/threonine kinase consisting of mul-
tiple protein-binding motifs that enable interaction and
phosphorylation of many proteins and is considered a
central signalling molecule for convergence and crosstalk
between multiple pathways. mTOR phosphorylates and
activates the translational machinery proteins: eukaryotic
translation initiation factor 4E- (eIF-4E-) binding protein
(4E-BP1) and p70 S6 kinase. Upon phosphorylation, 4E-
BP1 no longer interacts with and represses eIF-4E, and p70S6
phosphorylates and activates the 40 S ribosomal protein.
Activation of both eIF-4E and the 40 S ribosomal protein
initiates translation of HIF-1α mRNA (Figure 3)[ 48, 49].
Stimulation of PI3K signalling by activation of diﬀerent
RTKs in a variety of cancer types induces protein synthesis
of HIF-1α. This has been shown in colon and breast
cancer cells via activation of IGF-1R and HER2nueRb y
IGF-1 and heregulin, respectively, [37, 50]. Stimulation of
PI3K/AKT/mTOR induces the activation of the transla-
tional machinery proteins and protein synthesis of HIF-
1α.H E R 2 neu is an indicator for poor prognosis in breast
cancer and tumours overexpressing HER2 have increased
angiogenesis due to increased expression of the HIF-1 target
gene VEGF. Similarly, overexpression of HIF-1α and VEGF
has been found in prostate cancer cells that have hyperactive
PI3K/AKT/mTOR activity as a result of enhanced EGFR
signalling [51].
Depending on the type of RTK that is activated and
o nt h et y p eo fc a n c e r ,i n c r e a s e dH I F - 1 α protein may be
PI3K dependent even in the presence of activated MAPK
signalling or may be dependent on both signalling pathways.
Oestrogen-dependent tumours usually display hyperactive,
PI3K, HIF-1α, and VEGF signalling. Studies on the eﬀect of
oestrogen induced HIF-1α and VEGF in rat uterine tissue
have shown that although oestrogen receptor signalling
stimulates both the PI3K and MAPK signalling cascades,
induction of HIF-1α and VEGF was only dependent upon
PI3Ksignalling [52].However,inHCT116coloncancercells,
IGF-1 induced HIF-1α protein synthesis involved both the
PI3K and MAPK signaling pathways [37]. Enhanced activity
of HIF-1 by growth factor receptor signalling pathways is
both receptor and cell speciﬁc and highlights the complexity
of HIF-1 regulation by these signalling cascades.
Lossofnegative regulatorsofthePI3Kpathwayincluding
PTEN, p53 and the tumour-suppressor proteins tuberous
sclerosis proteins TSC1 (hamartin), TSC2 (tuberin), and
promyelocytic leukemia (PML) leads to hyperactive PI3K-
signalling. PTEN is a phosphatase that dephosphorylates
the PI3K products, and thus inhibits PI3K downstream
signalling. Loss of PTEN or loss of function of PTEN has
been found in a range of cancers including prostate, glioma,
and thyroid [53–55]. Loss of PTEN has been associated
with enhanced angiogenesis and cancer progression possibly
through PI3K-induced HIF-1α and downstream targets
including VEGF. Loss of function or deletion of the tumour
suppressor p53 is common in many cancer types includingJournal of Thyroid Research 5
(p42/44)
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Figure 2: Regulation of HIF-1α by the MAPK pathway. Stimulation of receptor tyrosine kinases (RTKs) by growth factors, or activating
mutations in the RAS family of GTPases, such as KRAS, results in activation of a range of MAPK-signalling proteins. Activation of ERK1/2
by MEK1/2 increases HIF-1 signalling (a) by phosphorylating and promoting the interaction of the coactivator p300 with HIF-1α and
(b) by phosphorylating and activating the translational regulatory protein p70S6K and by phosphorylating and disrupting the repressive
interaction of 4E-BP1 with eIF-4E. Activation of these translational machinery proteins leads to increased protein synthesis of HIF-1α.
Activation of MAPKs (p38/p38γ) leads to the direct phosphorylation and activation of HIF-1α. Additionally, under hypoxia, activation of
the small GTPase Rac1 leads to a Rac1 dependent increase in HIF-1α activity via Rac-1 induced activation ofp38 MAPK. Genetic mutations
in members of the MAPK signalling pathway such as those in BRAF (BRAFV600E) lead to hyperactive MEK/ERK signalling and enhanced
HIF-1α activity.
thyroid. p53 negatively regulates the PI3K pathway by
inhibiting transcription of the PIK3CA gene that encodes
the catalytic subunit of PI3K; p110α and by activating
transcription of PTEN and TSC2 [56, 57]. Furthermore, p53
can directly interact with HIF-1α and recruit MDM2, which
targets HIF-1α for ubiquitination and degradation [28, 58].
mTOR activity is negatively regulated by the heterodimer
TSC1 (hamartin) and TSC2 (tuberin). This complex is
disrupted and functionally inactivated by AKT leading to
enhanced activity of mTOR and upregulation of HIF-1α.
This has recently been conﬁrmed in irradiated tumours
where HIF-1α is activated through this pathway [59]. HIF-
1α is not only stimulated through PI3K/AKT activation
of mTOR via loss of the TSC1/2 complex, but also via
mutational changes leading to loss of TCS2 function. Sub-
sequently, HIF-1α downstream targets including VEGF and
Glucose transporter-1(GLUT-1) are increased [60]. Hypoxia
inhibits mTOR activity in both a HIF-dependent and
independent manner [61]. Under hypoxia, PML negatively
regulates mTOR by directly interacting with and preventing
activationofmTORbythesmall GTPase Rheb1.LossofPML
is observed in a number of sporadic tumours and correlates
with increased VEGF and HIF-1α expression via attenuation
ofhypoxicmTORinhibition[62].Characteristically,patients
withmTOR-associated hamartoma and tumoursharbouring
mutations in TSC2 and PML are highly vascularised, a com-
mon phenotype of tumours arising from mutations in VHL,
which have hyperactive HIF-1 and VEGF signalling [60, 62].
Collectively, these tumour types highlight the importance of
HIF-1 in tumour angiogenesis and progression.
Studies in human embryonic kidney cells suggest that
mTOR maydirectlyphosphorylateHIF-1α,promotingbind-
ing of p300/CBP and enhancing HIF-1α activity. mTOR
interacts with the scaﬀold protein raptor (regulatory-
associated protein of mTOR). Raptor directly interacts with
HIF-1α under conditions favouring stabilisation of HIF-1α,
thatis,hypoxia,resulting inenhancedactivity, which was not
due to mTOR induced stabilisation of HIF-1α protein [63].
The pathophysiology behind increased HIF-1α in many
solid tumours is not only restricted to hypoxia, growth
factor signalling cascades, or mutations in components of
the oxygen-dependent regulatory mechanism of HIF-1, but
a l s om a yb em e d i a t e db yo t h e rs i g n a l l i n gp a t h w a y s .Ah y p e r -
active Wnt/β-catenin signalling cascade may similarly result
in increased activity of HIF-1 due to the interaction of
β-catenin with HIF-1α [64, 65]. Collectively, these data
highlight that many pathways are involved in the ﬁne tuning
of HIF-1α regulation by oncogenic signalling cascades such
as the ERK-MAPK and PI3K/AKT pathways.
4.The RoleofHIF inCancer
The majority of solid tumours encounter hypoxic stress as
ar e s u l to f( a )l i m i t e do x y g e nd i ﬀusion due to the rapid
proliferation of tumour cells which outgrow the existing
vascular network and (b) by perfusion deﬁcits mediated by6 Journal of Thyroid Research
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Figure 3: Regulation of HIF-1α by the PI3K pathway. Stimulation of receptor tyrosine kinases (RTKs) by growth factors or activating
mutations in the RAS family of GTPases, such as KRAS, results in activation of PI3K. Activated PI3K enables the phosphorylation and
activation of AKT. AKT in turn activates mammalian mTOR by disrupting the inhibitory interaction of the TSC1/TSC2 complex with
mTOR. mTOR enhances HIF-1 signalling in a multimechanistic way (a) By activating the translational machinery proteins p70S6K and EIF-
4E leading to enhanced protein synthesis of HIF-1α and (b) By promoting the interaction of HIF-1α with the coactivator p300, possibly
by direct phosphorylation of HIF-1α via interaction with the scaﬀold protein raptor. Additionally, deletion or loss of function of negative
regulators of the PI3K pathway leads to enhanced signalling and activation of HIF-1. These include PTEN, p53, PML, and TSC1/2. The
phosphatase PTEN dephosphorylates the products of PI3K, inhibiting activation of AKT and subsequent downstream targets. p53 inhibits
PI3K signalling at multiple levels; p53 inhibits transcription of the catalytic subunit of PI3K (p110α), enhances transcription of PTEN and
TSC2, interacts with HIF-1α, and recruits MDM2, targeting HIF-1α for proteosomal degradation. PML inhibits mTOR under hypoxia and
TSC1/2 interacts with and prevents activation of mTOR in the absence of PI3K activation.
abnormal blood vessel structure and function within the
tumour [3, 66, 67]. Exposure to low oxygen tensions results
in enhanced expression and activity of HIF-1α leading to
increased tumour cell survival and growth under stressful
environments. Over one hundred HIF target genes have
been identiﬁed. HIF promotes tumour cell survival and
progression by regulating multiple genes including those
involved in angiogenesis (VEGF), anaerobic metabolism
(GLUT-1), control of intracellular pH (CA-9), regulation of
cellcycle,DNAdamageresponse, proliferationandapoptosis
(p21 and p27) and extracellular matrix remodelling and cell
migration(lysyloxidase(LOX),andmatrix-metalloprotease-
1 and -9 (MMP-1 and -9)) [68–71].
Clinically, hypoxia and HIF-1 has been associated with
poor prognosis in a range of cancers including uterine,
breast, and nonsmall cell lung cancer as well as poor
treatment response in cancers such as nasopharyngeal
cancer [1–3, 72]. Additionally, coexpression of HIF-1α
with other pro-oncogenic proteins has been shown to be
a signiﬁcant prognostic predictor of survival. In patients
with nonsmall cell lung cancer, coexpression of HIF-1α
with Snail or TWIST1 has been shown to reduce overall
survival and recurrence-free survival [73]. Expression of
HIF-2αandcoexpression with EGFRandinsulin-like growth
factor-binding protein-2 (IGFBP-2) has also been linked
to reduced survival in patients with higher grade astrocy-
tomas [74].
The HIFs act as the most important sensors of oxygen
homeostasis. Constant HIF activation is a common feature
in many cancers and is becoming increasingly recognized as
a target for therapeutic intervention.
5.HIF andChemo/Radiotherapy
5.1. HIF and Chemoresistance. HIF-1α has been found to
upregulate expression of the ATP-binding cassette (ABC)
transporter family of proteins and multidrug resistance
related proteins (MRPs) in certain tumours and cancer cell
lines. The ABC-transporter proteins can eﬄux chemother-
apeutic agents out of the cell, namely, taxanes or anthracy-
clines resulting in reduced cytotoxicity and cell death [75–
77].
The HIF-1downstream target VEGF hasalso beenimpli-
cated in chemoresistance. Blockade of VEGF signalling can
promote normalisation of the tumour vasculature resulting
in enhanced delivery of chemotherapeutics into the tumour.
This has been observed in anaplastic thyroid carcinoma
xenografts,wherebevacizumab(inhibitorymonoclonalanti-
body against VEGF) lowered tumour interstitial pressure and
reduced vascular permeability [78]. Due to enhanced VEGFJournal of Thyroid Research 7
signalling, the tumour vasculature is erratic, dysfunctional,
and leaky, resulting in poorly perfused regions and high
tumour interstitial pressure. This can hinder diﬀusion of
chemotherapeutics into the tumours [79]. Qayum et al.
recently showed that blockade of the EGFR, RAS, and
PI3K pathways leads to long-term morphological changes
that promote increased perfusion and allow prolonged and
enhanced drug delivery to the tumour. These changes may
also improve tumour response to radiotherapy [80]. In
addition to VEGF being a HIF-1 downstream target, VEGF
itself can induce HIF-1α and promote HIF-1 activity leading
to enhanced chemo-resistance.
Other HIF-1 target genes implicated in chemo-resistance
includeCA-9.CA-9playsaroleinacidiﬁcationofthetumour
microenvironment by catalysing the hydration of CO2 to
bicarbonate and protons. Due to this, anticancer drugs that
are weakly basic are unable to be taken up eﬀectively into
tumour cells as a result of raised intracellular pH and low
extracellular pH, leading to reduced cytotoxicity [81–83].
Additionally, our group has shown that inhibition of HIF-1α
either genetically or pharmacologically can enhance chemo-
sensitivity when used in combination with drugs that lack
eﬃcacy in hypoxic cells such as etoposide [84].
Collectively, these data highlight the importance of
HIF-1 in chemo-resistance and suggest that combination
treatments with HIF inhibitors may be useful in improving
therapeutic response to existing drugs and especially those
associated with hypoxic chemo-resistance.
5.2. HIF and Radioresistance. Tumour hypoxia is associated
with radioresistance due to the lack of oxygen leading to
a reduction in the level of radiation-induced free radicals.
These free radicals induce single- and double-stranded DNA
breaks,leading tocelldeathby necrosis, apoptosis, or mitotic
catastrophe [85, 86]. Within a tumour, the level of hypoxia
has been shown to inversely correlate with radiosensitivity
[66]. HIF-1 signalling promotes cell survival following
exposure toionising radiation. Clinically, high HIF-1activity
afterradiationisassociated withpoorprognosis [2,87].HIF-
1 activity has been found to increase with increasing doses of
radiation in tumour xenograft models. No eﬀect of radiation
on HIF-1 activity was observed in tumour cells in vitro,
suggesting that increased activity is dependent on radiation-
induced physical changes within the intact tumour [88].
Conversely, other studies suggest that radiation itself can
increase HIF-1α expression in addition to hypoxia in vitro.
HIF-1reporter activity was found toincrease in hypoxic cells
following exposure to radiation in range of carcinoma cell
lines [89]. As a result of radiation-induced HIF-1 signalling,
expression of HIF-1 downstream targets such as VEGF,
plasminogen activator inhibitor-1, and CA-9 are increased
and promote radio-resistance [90].
Within a tumour, mechanisms thought to contribute
to radiation induced increases in HIF-1 include tumour
reoxygenation. Radiation increases the level of O2 within a
tumour. This is due to cell death of well-oxygenated cells
that frees up O2 molecules. Additionally, as there are fewer
tumour cells due to cell death, the vasculature is able to
expand and grow, leading to enhanced oxygenation. This
reoxygenation causes the generation of free radical such as
reactive nitrogen species that lead to inhibition of the PHDs,
thus reducing proteosomal degradation of HIF-1α [91].
Hyperactivity of growth factor signalling pathways such
as EGFR, RAS, and PI3K/AKT cascades have been linked
to radio-resistance and tumour cell survival following
radiotherapy [92, 93]. As HIF-1 is a downstream target of
PI3K, PI3K-induced HIF-1 activity may contribute to radio-
resistance. Therefore, it is feasible to assume that tumour
cells associated with hyperactive PI3K signaling, and thus,
HIF-1activitymayrespondbettertoradiotherapywhenused
in combination with a PI3K inhibitor. Currently, inhibition
at the level of the EGFR in combination with radiotherapy
has been used clinically and with success in certain tumour
types [92, 94]. However, as there are many diﬀerent points
of activation within the PI3K signalling pathway, inhibition
of PI3K itself may be useful in a whole range of tumours
thathavehyperactive PI3Ksignalling which isnotdependent
on EGFR activation but are dependent on other RTKs.
Enhanced radiosensitivity has been observed in colon car-
cinoma cells treated with the selective PI3K inhibitor PI-
103 [95] and in glioma xenografts treated with selective
small molecule inhibitors of p110α [96]. Thus, these data
provide promising evidencethatin addition to inhibiting the
downstream eﬀects of PI3K that promote cell survival after
radiation, indirect targeting of HIF-1by PI3K inhibitors may
signiﬁcantly contribute to enhanced radiosensitivity.
6.HIF andThyroid Hormones
Thyroid hormones play a key role in growth, metabolism
and development. The eﬀects of these hormones are
brought about, namely, by the thyroid hormone ligand
3,3,5-triiodothyronine (T3) binding to the nuclear thyroid
hormone receptors (TR) β1, β2, or α1. The ligand-nuclear
receptor complex recruits additional proteins and acts as
transcription factorsthatregulategeneexpressionbybinding
to the thyroid hormone response elements (TREs) in the
promoter region of target genes. These genomic actions
of thyroid hormones usually involve the binding of T3 to
monomers, homodimers, or as heterodimers of the TRs with
another member of the nuclear hormone receptor family
such as the retinoid X receptor. This results in shedding
of corepressors and recruitment of co-activators leading to
alterations in transcription of thyroid hormone responsive
genes [97, 98]. This contrasts to the rapid, nongenomic
actions of thyroid hormones on the activity of ion pumps,
cytosolic signalling, mitochondria, and the intracellular
protein traﬃcking from cytosol to nucleus [98].
Thyroid hormones can activate both the PI3K and
MAPK-signalling cascades [98–101]. Furthermore, thyroid
hormones have been found to directly regulate expression of
HIF-1α via activation of these signal transduction pathways.
Microarray analysis of T3 regulated genes in human skin
ﬁbroblasts revealed an upregulation of HIF-1α and HIF-
1 target genes GLUT1, platelet-type phosphofructokinase
(PFK) and monocarboxylate transporter-4 (MCT-4) via8 Journal of Thyroid Research
T3/TRβ signalling. The speciﬁcity of this upregulation by
T3 was conﬁrmed in ﬁbroblasts from patients with an
inactivating mutationinTRβ. These ﬁbroblasts didnot show
any such changes in gene expression of HIF-1α and target
genes [99]. The direct upregulationof HIF-1αby T3 resulted
in a T3 indirect increase of GLUT-1, PFK, and MCT-4
expression via enhanced HIF-1α activity. This direct increase
in HIF-1α activity was due to T3/TRβ activation of PI3K
(Figure 4). Other studies have also shown that a TRβ mutant
(TRβPV/PV) interacts with the PI3K-regulatory subunit p85α
leading to enhanced PI3K signalling, promoting thyroid
carcinogenesis in a mouse model of spontaneous follicular
thyroid cancer (thyroid hormone receptorPV/PV mice) [100].
This may lead to enhanced HIF-1α signalling in vivo.
T3 can also increase HIF-1α expression through inter-
action with the TRα members. In endothelial cells, T3
promotes the interaction of TRα1w i t ht h eP I 3 Ks u b u n i t
p85α, leading toincreased phosphorylation and activation of
AKT and endothelial nitric oxide synthase (eNOS). This is
thought to contribute to the vasodilatory and cardiovascular
protective eﬀects of thyroid hormones [101]. It is likely that
this T3-induced PI3K activity in endothelial cells would
enhance HIF-1α activity, which may contribute to the vascu-
lar eﬀects of thyroid hormone, as eNOS is a HIF-1 regulated
gene [102]. In glioma cells, stimulation of PI3K/AKT by T3
induces shuttling of TRα from the cytoplasm to the nucleus,
and promotes transcription of HIF-1α mRNA (Figure 4).
This T3-dependent process was inhibited by treatment with
the PI3K inhibitor LY294002 but not by the ERK inhibitor
PD098095 [98]. T3-induced expression of HIF1-α and the
downstream target VEGF has been veriﬁed in a gastric
cancer cell line and in vivo mouse model. Accumulation
of HIF-1α was due to T3 dependent activation of the
PI3K signalling cascade. Interestingly, in addition to PI3K-
signalling, HIF-1α overexpression by T3 may be regulated by
fumarate accumulation; this accumulation was enhanced by
T3-mediated inactivation of fumarate hydratase and reduced
inthepr esenceof2-o x oglutarate[103](Figure 4).These data
link thyroid hormones with metabolic proteins and the HIF-
1 signalling pathway in carcinogenesis and provide a means
for understanding the adaptive mechanisms of tumour cells
to metabolic stress.
Interestingly, T4 but not T3 has been found to impact on
HIF-1α expression via interaction with the TRβ1 in glioblas-
toma (U-87) cells. This process was dependent on MAPK
(ERK1/2)signalling asPD098095inhibitedT4-inducedHIF-
1α expression [98]. In CV-1 cells transfected with TRβ1,
T4-activated MAPK signalling led to the interaction of
MAPK with TRβ1 and enhanced phosphorylation and TRβ1
signalling [104]. Other studies have shown that both T3
and T4 can promote HIF-1α activity by activating the PI3K
pathway. In hepatoma cells, T3 and to a lesser extent T4
increased expression of the HIF-1 target genes EPO and
adrenomedullin (ADM), by stimulating the PI3K pathway,
thus leading to increased translation of HIF-1α mRNA. No
eﬀects on HIF-1α protein stability/proteosomal degradation
were observed [105].
In addition to the rapid nongenomic induction of HIF-
1α by thyroid hormones via activation of growth factor
signalling cascades, thyroid hormones have been shown to
induce HIF-1αvia the classic genomic actions of TRs. T3 can
indirectly increase HIF-1α mRNA in a range of carcinoma
cell lines that express hepatic leukemia factor (HLF). This
regulation appears to be independent of a major protein
kinase pathway, as the inhibition of members of both the
MAPK and PI3K kinase pathways, including mTOR, had no
eﬀect on T3-mediated HIF-1α expression. T3 induction of
HIF-1α was dependent on HLF-mediated gene expression of
HIF-1α. This stimulation of HLF was in turn mediated by
T3-activation of the TRβ-retinoid X receptor α heterodimer.
Increased HIF-1α was, therefore, solely at the mRNA level
and independent of translation [106]( Figure 4).
A close link between thyroid hormones and HIF is
further substantiated by data on the activity of deiodinase
type 3 (DIO3). Hypoxia induces DIO3, the physiological
inactivator of T3, which catalyses the conversion of T3 to
the metabolically inactive T2 (Figure 4). As this eﬀect was
also mimicked by hypoxia mimetics such as cobalt chloride,
a direct action of HIF-1 was suspected. HIF-1α directly
interacts with the DIO3 promoter, and thus stimulates DIO3
activity. This, in turn, induces a reduction of T3-dependent
activation of metabolic pathways and represents a protective
mechanism to reduce metabolic rate in tissues subjected to
hypoxia [107].
The eﬀect of T3 and T4 on HIF-1α is both receptor
andcellspeciﬁc.Furthermore,interactionofthesehormones
with additional signalling cascades provides insight into the
importance of thyroid hormones in driving carcinogenesis
by upregulating prosurvival pathways and those involved
in the adaptation to the stressful conditions of the tumour
microenvironment. An understanding of how these hor-
mones and their receptors diﬀerentially regulate HIF-1α in
both normal tissue and cancer may help identify the most
appropriatedrugtreatment toimprovetherapeuticresponse.
7.HIF andThyroid Cancer
7.1. Clinical Signiﬁcance of HIF-1 and Thyroid Carcinomas.
Recently we expanded on the potential pathophysiological
importance of HIF-1α in thyroid carcinomas by showing
that HIF-1α protein was variably expressed in primary
thyroidcarcinomas associatedwithadvancing tumourgrade.
Tumour samples were representative of papillary (PTC),
follicular (FTC), and anaplastic (ATC) thyroid carcinomas
[26]. HIF-1α expression was absent from normal thyroid
tissue. Interestingly and consistent with previous ﬁndings in
arangeofcancers,HIF-1αexpressionwashighest inthemost
aggressive dediﬀerentiated anaplastic thyroid carcinomas
(ATCs). However, analysis of vessel number and distribution
via Von Willebrand factor (vWF) immunostaining were
unable to link HIF-1α expression and vessel distribution.
This may have been expected due to the short half-life of
HIF-1α and transient regions of hypoxia that occur as a
result of the erratic and dysfunctional vasculature, HIF-1α
expression may not always be detected. Similarly to HIF-
1α, highest expression of GLUT-1 was observed in ATCs and
cell lines derived from ATCs, with lower expression observedJournal of Thyroid Research 9
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Figure 4: Thyroid hormone-dependent activation of HIF-1α:T 3a n dT 4i n d u c eH I F - 1 α activity by both genomic and nongenomic
mechanisms. Genomically, T3 indirectly increases HIF-1α mRNA by increasing expression of the transcription factor hepatic leukemia
factor (HLF), which initiates transcription of HIF-1α. Non-genomically,T3 stimulates PI3K signallingby promoting the interaction of both
TRα and β with the PI3K regulatory subunit p85 leading to enhanced PI3K/AKT/mTOR activity and translation of HIF-1α mRNA. T3-
induced PI3K promotes nuclear shuttling of TRα leading to increased HIF-1α expression. T3-induced PI3K signalling by either TRα or β
is cell speciﬁc. T3 inhibits the enzyme fumarate dehydrogenase resulting in the accumulation of fumarate. Fumarate inhibits PHD2 leading
to reduced hydroxylation of HIF-1α and increased protein stabilisation. T4 increases HIF-1α by stimulating MAPK signalling, leading to
enhanced T4/TRβ activity and expression of HIF-1α.A c t i v a t e dH I F - 1 α by T3/T4 results in the upregulation of target genes, known to
promote tumour cell survival and progression. These include GLUT-1, PFK, MCT-4, and VEGF. Additionally, HIF-1 upregulates DIO3,
which inhibits T3 by catalysing the conversion of T3 to the metabolically inactive T2.
in cell lines derived from diﬀerentiated tumours. These
increases, however, were only slight and were not signiﬁcant.
In contrast to GLUT-1, the HIF-1 downstream target CA-
9 closely mimicked the pattern of HIF-1α expression with
signiﬁcantlyhigherlevelsobservedintheATCs.Thissuggests
that CA-9 as in other cancer types may serve as a potential
new biomarker of aggressive disease in thyroid carcinomas.
This observation has been supported by previous work by
Jubb et al. who reported high expression levels of HIF-
1α in all thyroid carcinoma types particularly in FTCs
[29, 108]. Additionally, data from a preliminary study in
our group looking at HIF-1α and CA-9 in PTC, FTC, and
ATC xenografts showed a similar correlation to that seen
in clinical samples; both HIF-1α and CA-9 expression was
highest in the tumours derived from ATC (8505c) cells.
Furthermore, tumours with high expression of HIF-1α and
CA-9 had a greater number of spontaneous metastatic
colonies to the lungs (Figure 5). Collectively, these data from
primary tumour tissue and xenografts suggest that HIF-1α
expression is involved in the adaption of thyroid carcinomas
tohypoxiaandsupportsapathophysiologicalroleforthyroid
tumour progression, aggressiveness and metastasis.
7.2. Hypoxia and HIF-1 in Thyroid Carcinomas. An u m b e r
of functional studies in thyroid carcinoma cell lines and
in immortalized cells derived from normal thyroid tissue
substantiate the importance of hypoxia-induced HIF-1 in
promoting the expression of proteins that drive thyroid
tumour progression. HIF-1α was predominantly localized in
the cytoplasm under normoxia but stabilised and translo-
cated to the nucleus in hypoxia [29]. Enhanced nuclear
localisation of HIF-1α has also been observed in the BcPAP
cell line harbouring the BRAFV600E mutation versus a cell
line with WT BRAF under normoxia [30]. The functional
response of both normal and carcinoma thyroid cell lines to
hypoxia was further conﬁrmed as graded hypoxia-induced a
marked increase in expression of HIF-1α and downstream
targets CA-9, VEGF and GLUT1. Hypoxia induced HIF-
1α was further supported by HIF-1α reporter activation in
cells exposed to lowering oxygen tensions. Furthermore, the
degree of hypoxia induced HIF-1α activity related to the
level of thyroid carcinoma aggressiveness; lowest activity was
observed in PTC cell lines, with highest seen in ATC cells.
We have also conﬁrmed that hypoxia induces expression of
HIF-2α in follicular and anaplastic thyroid carcinoma cell
lines (unpublished, data not shown). This is of interest,10 Journal of Thyroid Research
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Figure5:HIF-1αandCA-9proteinexpressionandmetastaticpotentialarehighestintumoursderived fromfollicular(WRO)andanaplastic
(8505c) cell lines. Brieﬂy, BcPAP, FTC133, WRO and 8505c cells were implanted sub-cutaneously in female CBA nu/nu nude mice. Once
tumours reached 450mm3, tumour tissue and fresh lung tissue were excised. Tumour sections were immuno-stained for HIF-1α. Freshly
excised lung tissue was enzymatically digested, plated out in serial dilution and left until visible colonies formed. Colonies were stained,
countedandnumberofmetastaticcoloniespermglungtissuecalculated.(Forfullmethods,seesupplementarymaterialsandmethodswhich
is located at doi: 10.406/2011/762905). (a) Immunohistochemical staining for HIF-1α (brown staining). One example of HIF-1α staining
for each tumour type: BcPAP, FTC133, WRO and 8505c are displayed. (b) Semiquantitative analysis of HIF-1α and CA-9 immunostaining
quantiﬁed according to Allred et al. [109]. The total score is representative of intensity and proportion of staining. HIF-1α was highly
expressed in all tumour types with highest expression observed in the 8505c tumours. CA-9 was also expressed in all tumour types with
signiﬁcantly higher expression observed in 8505c tumours (P<. 05, one way Anova, with Tukey post test). (c) The number of spontaneous
metastatic colonies cultured from enzymatically digested lung tissue that was excised from mice bearing WRO, 8505c, FTC133, and BcPAP
tumours. The highest number of colonies counted were from the lungs of mice bearing FTC (WRO) and ATC (8505c) tumours. Data are
representative of the mean ± S.D. of 5 independent mice for each tumour type.
as the HIFs are known to regulate genes diﬀerentially in
many diﬀerentcancertypes. Therefore, expression in thyroid
carcinoma may account for some of the phenotypic diﬀer-
ences seen between the diﬀerent classiﬁcations of thyroid
carcinoma.
7.3. Growth-Factor Signalling Pathways and HIF-1 in Thyroid
Carcinomas. We found that in addition to hypoxia, growth
factor-signalling pathways also induced HIF-1α expression
and activity in thyroid carcinoma cell lines. Induction of
HIF-1α by pathways such as the MAPK and PI3K signalling
cascades have been described in a range of cancer types
(see oxygen-independent regulation of HIF) [110]. The
majority of thyroid carcinomas have mutations in growth
factor signalling pathways. Mutations in the BRAF gene
(BRAFV600E) leading to hyperactive MAPK/ERK signalling
have been found in approximately 50% of all PTCs [38].
Recently, this mutation has been reported to increase the
transcription and expression of HIF-1α protein [30].
KRAS has been found to diﬀerentially regulate HIFs
in certain cancer types [44]. Activating mutations in the
RAS family of GTPases, such as those found in KRAS,Journal of Thyroid Research 11
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Figure 6: Mechanisms of induction of HIF-1α and downstream eﬀects of HIF-1 signalling in thyroid carcinomas. HIF-1 activity is induced
not only by hypoxia but by the oncogenic MAPK and PI3K signalling pathways. Clinically, expression of HIF-1α and the downstream target
CA-9 have been linked with thyroid carcinoma aggressiveness. It is well known that HIF-1 plays an important role in tumour development,
metastasis,and aggressiveness and is ultimately correlated with poor prognosis. Enhanced HIF-1 signallingby hypoxia and the PI3K/MAPK
pathways may play an important role in the metastatic characteristics of thyroid carcinoma. HIF-1-induced MET upregulation has been
implicated in promoting invasiveness of PTC. HIF-1 signalling may also play a prominent role in the therapeutic response to radiotherapy
in thyroid carcinoma.
have been found in approximately 20% of PTCs and more
speciﬁcally the follicular variant of PTC suggesting the
mutation promotes aggressive phenotype [43]. As KRAS
activates both BRAF and PI3K, it would be interesting to
determine the role of KRAS in the context of HIF activity
and aggressive phenotype in thyroid tumours and thyroid
carcinoma cell lines harbouring this mutation.
Studies have shown that highest levels of HIF-1α expres-
sion and activity were detected in thyroid tumours and
tumour cell lines harbouring classic mutations in BRAF
and PI3K [29, 30]. Thus, the current data supports the
importance of oncogenic activation of HIF-1 in thyroid
cancer and aggressive disease [46]. Direct intervention with
pharmacological inhibitors of these pathways (LY294002 for
PI3K, PD098059 for ERK/MAPK, and sorafenib for inhibi-
tion of RAF-1 kinase/BRAF) or by genetic modulation; (re-
expression of PTEN in PTEN null cell lines and silencing of
mutant BRAF),further support the close dependency of HIF
expression on oncogenic signalling. Interestingly, inhibition
of HIF-1α reporter activity was much more substantial as
a consequence of LY294002 treatment under varying O2
tensions compared to PD98059 even in cell lines with no
k n o w nm u t a t i o ni nt h eP I 3 Kp a t h w a y .T h e s eﬁ n d i n g sa r e
particularlyinteresting withregard tothefrequentmutations
i nt h eP I 3 K / A K Tp a t h w a yf o u n di nu pt o1 5 %o fP T C
and approximately 50% of FTC [111, 112], where PI3K-
pathway mutations have been directly linked to tumour
aggressiveness [41]. HIF-1α silencing reduced expression of
HIF-1 target genes like CA-9. Thus, blocking HIF-1α,e i t h e r
directlyorthroughinhibition ofthe PI3Kpathwayin thyroid
carcinomas, may decrease aggressiveness and thus open new
therapeutic options [46].
7.4. HIF and VEGF in Thyroid Carcinomas. VEGF serum
levels are elevated in thyroid carcinomas, and this is asso-
ciated with poor tumour prognosis [113–116]. As one of
the most important downstream targets of HIF-1 signalling,
VEGF has not yet been linked clinically to HIF activity in
thyroid carcinomas. A number of studies using antagonists
of VEGF signalling for the treatment of advanced thyroid
carcinomas have been reported with some positive results
([117–120]. However, no data are currently available on
the eﬀect on VEGF levels by direct targeting of HIF-1. We
have reported that VEGF levels are signiﬁcantly increased
by anoxia in thyroid carcinoma cells lines derived from
PTC, FTC and ATC. Additionally, highest basal levels of
VEGF were observed in the PTEN—null FTC133 follicular
thyroid carcinoma cell lines [29]. This suggests that the
two diﬀerent signalling pathways may act synergistically
to increase VEGF. The anoxia-induced increases in VEGF
expression did not, however, match the pattern of HIF-1α
reporter activity in varying thyroid carcinoma cell lines. This
suggests that the level of dependency on either the HIF-
1 or growth factor-signalling pathways to induce VEGF is
speciﬁc to the type of thyroid carcinoma cell line. Current
unpublished data from our group supports a prominent
role and an important link between the PI3K and HIF-
1 pathways in the regulation of VEGF. Furthermore, we
have found that inhibition of these pathways has profound
eﬀects on VEGF expression in thyroid carcinoma cell lines.
These data provide a new angle for therapeutic approaches
of thyroid carcinoma as drugs which target HIF-1 signalling
may bemore eﬃcaciousindownregulating VEGF dependent
signalling in these tumours.12 Journal of Thyroid Research
7.5. HIF-1, Migration, and Metastasis in Thyroid Carcinomas.
Hypoxia and HIF-1 have been associated with increased
migration and metastasis in a range of cancer types [121–
123]. We have found that hypoxia signiﬁcantly increased
migration in cell lines derived from PTCs and FTCs. Addi-
tionally,we haveexcitingdata thatsupportsa prominentrole
of PI3K and HIF-1 signalling in metastatic characteristics of
FTC and ATC (unpublished).
Studies have shown a link between hypoxia/HIF-1α and
MNNG HOS transforming gene (MET) upregulation in
clinical PTCs. MET is a receptor tyrosine kinase that is
stimulated by hepatocyte growth factor (HGF). Stimulation
results in the activation of signal transduction pathways such
as PI3K, which promote migration, invasion, and the release
of cytokines and proangiogenic factors such as VEGF [124,
125]. Additionally, MET activation promotes migration and
invasion by stimulating the translocation of β-catenin from
the cytoplasm to the nucleus [126]. MET is highly expressed
inPTC,and this highexpression ofMET isthoughttobedue
to HIF-1 induced upregulation in hypoxic regions of PTCs.
Furthermore, higher expression of MET and HIF-1α mRNA
was found at the periphery of tumours (in cells located at
the invading front) compared to the centre in 44% of PTCs
[127]. These were characterised to have a more aggressive
phenotype. Collectively, these data suggest that HIF-1 may
play a role in promoting migration and aggressiveness in
PTC.
Taken together, these data highlight the importance
of hypoxia, HIF-1α and PI3K signalling as a means of
promoting metastatic characteristics and driving aggressive
disease in thyroid carcinomas (Figure 6).
8.HIF-1 andSensitivityto Radiotherapy
inThyroid Carcinomas
There is increasing evidence for the role of HIF in tumour
cell sensitivity to chemo- and importantly radiotherapy [77,
84, 128]. As discussed above, HIF-1 stabilisation and action
depend on growth factor-signalling pathways. Thus, many
inhibitors of growth factor signalling aﬀect HIF-1 expression
and downstream targets. Anticancer drugs that target these
pathways possess antiangiogenic properties and include
the BCR-ABL kinase inhibitor imatinib (Gleevec), EGFR
inhibitors such as geﬁtinib, erlotinib, and cetuximab, the
HER2neu inhibitor trastuzumab, and the mTOR inhibitors
rapamycin, temsirolimus, and everolimus. Collectively, these
drugs all target the translation of HIF-1α mRNA into
protein[129].ModulationofHIF-1αexpression canincrease
tumour sensitivity, in particular to radiotherapy in certain
cancer types (see HIF and radio-resistance). Thus, HIF-1
signalling may be a particularly important feature for the
sensitivity of dediﬀerentiated thyroid carcinomas to external
beam radiation. This has yet to be investigated.
It has been shown that tumour cell apoptosis is increased
when targeted radioiodide therapy is combined with angio-
genic inhibitors, which represents an indirect approach to
circumvent HIF-1—dependent radio-resistance [130]. Data
discussed here support the view that targeting of HIF-1 may
serve as a more direct approach to overcome HIF depen-
dent adaptation of thyroid carcinoma cells to radiotherapy.
Preliminary data from our group in FTC and ATC cell lines
supports this notion of HIF-1 signalling playing a role in
radio-resistance (unpublished). As described earlier, PI3K
has been found to play an important role in HIF-1α induced
expression and activity in thyroid carcinoma cell lines under
both normoxia and anoxia. Therefore, targeting HIF-1either
directly or by use of a PI3K-inhibitor may improve the
therapeutic response of thyroid carcinoma to radiotherapy.
Currently, there is no data available on whether inhi-
bition of HIF-1 may reﬂect on the sensitivity of more
diﬀerentiated tumours to standard radiotherapy. It is con-
ceivable that in patients receiving external beam radiation
treatment and particularly in patients with a poor response
but positive uptake of radioiodine, any augmentation of the
sensitivity towards irradiation-induced apoptosis would be
favourable(Figure 6).Studiesinourgrouponanimalmodels
of metastatic follicular and anaplastic thyroid carcinomas
will hopefully allow us to answers some of these questions
in the future.
9.Conclusions
HIF-1 is potently induced by both hypoxia and oncogenic
signalling pathways in thyroid carcinoma, and its expression
and activity have been correlated with aggressiveness. Cur-
rent literature suggests that PI3K and MAPK pathways pro-
mote aggressive and metastatic disease in part via the upreg-
ulation of HIF-1 activity. With the known eﬀects of hypoxia,
PI3K/MAPK pathways, and HIF-1 on desensitisation to
radiotherapy,HIF-1maybeanewandimportanttherapeutic
target in reducing local tumour growth, metastatic burden,
and radio-resistance in thyroid carcinoma.
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